scPharmaceuticals Inc. (SCPH)
Stock Price:
$8.03 USD
-0.20 (-2.43%)
Updated Jul 9, 2020 9:54 AM EDT - Market open
Key Info
| Market Cap |
215.13M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-31.37M |
| Shares Out |
26.79M |
| EPS (ttm) |
-1.65 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 9, 2020 |
| Last Price |
$8.03 |
| Previous Close |
$8.23 |
| Change ($) |
-0.20 |
| Change (%) |
-2.43% |
| Day's Open |
8.28 |
| Day's Range |
8.01 - 8.46 |
| Day's Volume |
8,171 |
| 52-Week Range |
3.40 - 11.99 |
More Stats
| Market Cap |
215.13M |
| Enterprise Value |
159.86M |
| Earnings Date (est) |
Aug 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
26.79M |
| Float |
7.16M |
| EPS (basic) |
-1.65 |
| EPS (diluted) |
-1.65 |
| FCF / Share |
-1.59 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
58,324 |
| Short Ratio |
0.30 |
| Short % of Float |
0.41% |
| Beta |
0.48 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.47 |
| Revenue |
n/a |
| Operating Income |
-30.75M |
| Net Income |
-31.37M |
| Free Cash Flow |
-32.07M |
| Net Cash |
55.27M |
| Net Cash / Share |
2.06 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-24.55% |
| ROE |
-49.99% |
| ROIC |
-206.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
3 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$13.50*
(68.12% upside)
Low
10.0
Current: 8.03
High
15.0
Target: 13.50
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -32.91 | -29.67 | -23.44 | -17.91 | -10.84 |
| Net Income | -33.00 | -29.44 | -23.82 | -24.38 | -10.52 |
| Shares Outstanding | 18.60 | 18.56 | 2.96 | 0.97 | 0.76 |
| Earnings Per Share | -1.77 | -1.59 | -8.04 | -25.01 | -13.78 |
| Operating Cash Flow | -30.44 | -28.81 | -22.68 | -15.46 | -9.64 |
| Capital Expenditures | - | - | -0.19 | -0.01 | -0.02 |
| Free Cash Flow | -30.44 | -28.81 | -22.88 | -15.46 | -9.66 |
| Cash & Equivalents | 72.81 | 89.66 | 118 | 39.28 | 1.57 |
| Total Debt | 20.27 | 11.34 | 11.34 | - | - |
| Net Cash / Debt | 52.54 | 78.32 | 107 | 39.28 | 1.57 |
| Assets | 77.28 | 93.76 | 122 | 39.77 | 1.85 |
| Liabilities | 25.92 | 15.01 | 16.05 | 3.74 | 2.01 |
| Book Value | 51.37 | 78.74 | 106 | -37.07 | -18.24 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
scPharmaceuticals Inc. |
| Country |
United States |
| Employees |
15 |
| CEO |
John H. Tucker |
Stock Information
| Ticker Symbol |
SCPH |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SCPH |
| IPO Date |
November 17, 2017 |
Description
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.